AMOYTOP(SH:688278) Zheng Quan Ri Bao Wang·2025-12-09 07:10Group 1 - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security have announced the inclusion of the new drug Yipeisheng (generic name: Yipei Growth Hormone Injection) developed by TeBao Bioengineering Co., Ltd. in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2025 Edition), effective from January 1, 2026, which will enhance drug accessibility and reduce the medication burden for a wider range of patients with dwarfism [1][2] - The prevalence of dwarfism among children in China is approximately 3%, corresponding to about 7.6 million patients, but the standardized treatment rate is less than 5%, with traditional treatment options being a significant limiting factor [1] - Yipeisheng is the world's first Y-type 40kD polyethylene glycol long-acting growth hormone, primarily used for treating growth retardation due to growth hormone deficiency in children aged 3 and above, featuring a structural modification that preserves biological activity and allows for weekly administration [1] Group 2 - TeBao Bio has focused on the research and development of long-acting protein drugs, particularly excelling in polyethylene glycol modification technology, establishing itself as a leading enterprise in the domestic long-acting protein field after nearly 30 years of technological accumulation [2] - In the first three quarters of 2025, the company's R&D investment reached 312 million yuan, a year-on-year increase of 38.53%, providing strong support for continuous innovation [2] - The company aims to continue increasing R&D efforts to launch more high-quality and accessible innovative treatment solutions, contributing to the standardized diagnosis and treatment of dwarfism and benefiting more children and families, aligning with the "Healthy China 2030" strategy [2]